Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for JNJ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Value Graph.
TapClick below to see what's inside, then upgrade to unlock for JNJ and 80,000+ other tickers.
The latest quarter of all 6 metrics Johnson & Johnson reports, from its segment revenue to its operating figures, each with its change from the quarter before and from a year earlier, and its history back to Dec 2019.
TapClick below to see what's inside, then upgrade to unlock it for JNJ and every other company we cover.
6 suppliers and 1 customer of Johnson & Johnson, named in SEC filings, company releases and earnings calls, with the quote behind each one, the share of revenue where a filing gives it, and how it moved.
TapClick below to see what's inside, then upgrade to unlock it for JNJ and every other company we cover.
See exactly how JNJ's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for JNJ and 80,000+ other tickers.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva production b in more than twice as many patients on nipocalimab compared to placebo c Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren's disease including these measures critical to patients NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease (SjD), a chronic, systemic autoantibody-driven disease affecting approximately four million people worldwide.1 The results show that mouth dryness is the symptom improvement that matters most to patients,2 complementing previously reported Phase 2 study results on increased saliva production in patients who received nipocalimab.3 This was also the most frequently reported symptom, with 96% of patients surveyed citing mouth dryness.2 These findings helped to inform the design of the ongoing Phase 3 study of nipocalimab in SjD, and are among 23 abstracts on nipocalimab to be presented at the American College of Rheumatology (ACR) Convergence 2026.
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16.2 Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified.
J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
